Bulevirtide-Lonafarnib Combination Therapy for HDV Entry and Replication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis D virus (HDV) infection are inadequate, particularly in the context of co-infection with hepatitis B virus (HBV), as existing therapies fail to effectively inhibit viral entry and replication.
Innovation Solution
A combination therapy using bulevirtide, a hydrophobic modified preS1-derived peptide, and lonafarnib, a farnesyltransferase inhibitor, is administered to patients to target HBV and HDV infection, inhibiting viral entry and replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing monotherapies are used for HDV infection, then treatment simplicity is maintained, but antiviral efficacy is insufficient
Solution Approach 1:
The patent combines two different antiviral mechanisms into a single treatment regimen: bulevirtide (an NTCP inhibitor that blocks viral entry) and lonafarnib (a farnesyltransferase inhibitor that disrupts viral protein processing). This combination therapy achieves synergistic antiviral efficacy against HDV while addressing the limitations of monotherapies.
2Reliability
If combination therapy with bulevirtide and lonafarnib is administered, then antiviral efficacy is improved, but treatment complexity increases
Solution Approach 1:
The patent establishes a universal combination therapy regimen that can be applied across different HDV infection scenarios (acute infection, chronic infection, co-infection with HBV). The fixed combination of bulevirtide and lonafarnib serves multiple therapeutic functions: blocking viral entry, disrupting viral protein maturation, and preventing viral assembly, simplifying clinical decision-making despite the multi-mechanism approach.
3Reliability
If bulevirtide is administered alone, then viral entry inhibition is achieved, but complete viral replication block is insufficient
Solution Approach 1:
The patent segments the viral replication process into distinct targets: bulevirtide targets the entry stage by blocking NTCP receptor interaction, while lonafarnib targets the post-entry stage by inhibiting farnesyltransferase-mediated protein processing. This segmentation allows each drug to specialize in a specific phase of replication, achieving comprehensive inhibition without requiring a single complex multi-functional agent.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy effectively inhibits HBV and HDV infection, preventing primary infection and treating chronic hepatitis B and D, with potential for prolonged administration and varying dosing regimens to optimize treatment outcomes.
Implementation Method 1
bulevirtide, a hydrophobic modified preS1-derived peptide
Implementation Method 2
inhibiting viral entry through the host sodium taurocholate co-transporting polypeptide (NTCP) on hepatocytes
Implementation Method 3
lonafarnib, a farnesyltransferase inhibitor
Data Source
AI summary
The present application provides combinations of bulevirtide, or a pharmaceutically acceptable salt thereof, and lonafarnib, or a pharmaceutically acceptable salt thereof, useful for treating hepatitis D virus (HDV) infection.